Single Agent Regorafenib in First-line for Metastatic/Unresectable KIT/PDGFR Wild Type GIST

PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

August 31, 2021

Study Completion Date

August 31, 2021

Conditions
Gastrointestinal Stromal Tumors
Interventions
DRUG

regorafenib

Treatment with regorafenib 160mg once a day, 3 weeks on / 1 week off in cycles of 28 days

Trial Locations (17)

28009

Hospital Universitario Gregorio Marañon, Madrid

28046

Hospital Universitario La Paz, Madrid

38320

Hospital Universitario de Canarias, San Cristóbal de La Laguna

41013

Hospital Universitario Virgen del Rocío, Seville

41071

Hospital Universitario Virgen de la Macarena, Seville

46009

Instituto Valenciano de Oncología, Valencia

48902

Hospital de Cruces, Barakaldo

50009

Hospital Universitario Miguel Servet, Zaragoza

80131

Fondazione G Pascale Napoli, Napoli

Unknown

Institute Bergonie, Bordeaux

Centre Leon Berard, Lyon

Gustave Roussy, Villejuif

Fondazione IRCCS Istituto Dei Tumori di Milano, Milan

Policlinico Universitario Campus Bio-Medico, Roma

Istituto di Candiolo - IRCSS, Torino

08035

Hospital Universitario Vall d´hebron, Barcelona

08041

Hospital de la Santa Creu i Sant Pau, Barcelona

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

Grupo Espanol de Investigacion en Sarcomas

OTHER